Format

Send to

Choose Destination
Cancer Lett. 2010 Jan 28;287(2):216-23. doi: 10.1016/j.canlet.2009.06.016. Epub 2009 Jul 25.

Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death.

Author information

1
Departamento de Morfología y Biología Celular, Spain. martinvanesa@uniovi.es

Abstract

Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

PMID:
19632770
DOI:
10.1016/j.canlet.2009.06.016
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center